🚀 VC round data is live in beta, check it out!
Macrogenics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Macrogenics and similar public comparables like Captor Therapeutics, Curatis Holding, Tenaya Therapeutics, Genelux and more.
Macrogenics Overview
About Macrogenics
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Founded
2000
HQ
Employees
341
Website
Sectors
Financials (LTM)
EV
$13M
Macrogenics Financials
Macrogenics reported last 12-month revenue of $139M.
In the same LTM period, Macrogenics generated $125M in gross profit and had net loss of ($77M).
Revenue (LTM)
Macrogenics P&L
In the most recent fiscal year, Macrogenics reported revenue of $150M and EBITDA of ($60M).
Macrogenics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $139M | XXX | $150M | XXX | XXX | XXX |
| Gross Profit | $125M | XXX | $113M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($60M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (40%) | XXX | XXX | XXX |
| EBIT Margin | (54%) | XXX | (49%) | XXX | XXX | XXX |
| Net Profit | ($77M) | XXX | ($75M) | XXX | XXX | XXX |
| Net Margin | (56%) | XXX | (50%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Macrogenics Stock Performance
Macrogenics has current market cap of $123M, and enterprise value of $13M.
Market Cap Evolution
Macrogenics' stock price is $1.94.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $123M | 0.0% | XXX | XXX | XXX | $-1.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMacrogenics Valuation Multiples
Macrogenics trades at 0.1x EV/Revenue multiple, and (0.2x) EV/EBITDA.
EV / Revenue (LTM)
Macrogenics Financial Valuation Multiples
As of March 18, 2026, Macrogenics has market cap of $123M and EV of $13M.
Equity research analysts estimate Macrogenics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Macrogenics has a P/E ratio of (1.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $123M | XXX | $123M | XXX | XXX | XXX |
| EV (current) | $13M | XXX | $13M | XXX | XXX | XXX |
| EV/Revenue | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.2x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| P/E | (1.6x) | XXX | (1.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Macrogenics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Macrogenics Margins & Growth Rates
Macrogenics' revenue in the last 12 month declined by (28%).
Macrogenics' revenue per employee in the last FY averaged $0.4M.
Macrogenics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (28%) | XXX | (33%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (40%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 4% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 105% | XXX | 98% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 125% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Macrogenics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Captor Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Curatis Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Tenaya Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Genelux | XXX | XXX | XXX | XXX | XXX | XXX |
| Cantargia | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Macrogenics M&A Activity
Macrogenics acquired XXX companies to date.
Last acquisition by Macrogenics was on XXXXXXXX, XXXXX. Macrogenics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Macrogenics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMacrogenics Investment Activity
Macrogenics invested in XXX companies to date.
Macrogenics made its latest investment on XXXXXXXX, XXXXX. Macrogenics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Macrogenics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Macrogenics
| When was Macrogenics founded? | Macrogenics was founded in 2000. |
| Where is Macrogenics headquartered? | Macrogenics is headquartered in United States. |
| How many employees does Macrogenics have? | As of today, Macrogenics has over 341 employees. |
| Who is the CEO of Macrogenics? | Macrogenics' CEO is Eric Risser. |
| Is Macrogenics publicly listed? | Yes, Macrogenics is a public company listed on Nasdaq. |
| What is the stock symbol of Macrogenics? | Macrogenics trades under MGNX ticker. |
| When did Macrogenics go public? | Macrogenics went public in 2013. |
| Who are competitors of Macrogenics? | Macrogenics main competitors are Captor Therapeutics, Curatis Holding, Tenaya Therapeutics, Genelux. |
| What is the current market cap of Macrogenics? | Macrogenics' current market cap is $123M. |
| What is the current revenue of Macrogenics? | Macrogenics' last 12 months revenue is $139M. |
| What is the current revenue growth of Macrogenics? | Macrogenics revenue growth (NTM/LTM) is (28%). |
| What is the current EV/Revenue multiple of Macrogenics? | Current revenue multiple of Macrogenics is 0.1x. |
| Is Macrogenics profitable? | No, Macrogenics is not profitable. |
| What is the current net income of Macrogenics? | Macrogenics' last 12 months net income is ($77M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.